Latest Pharmaceutical Supply Agreements News

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Clarity Pharmaceuticals has expanded its breast cancer pipeline by introducing 64/67Cu-SAR-trastuzumab, supported by promising pre-clinical data and a new supply agreement for trastuzumab, aiming to address the unmet needs in HER2-positive breast cancer treatment.